Top 14+ Cx-072 hay nhất
-
1.CX-072 (pacmilimab), A Probody® PD-L1 Inhibitor, In Advanced Or ...
23 thg 7, 2021 · CX-072 (pacmilimab) is a Probody therapeutic directed against PD-L1. In preclinical studies, pacmilimab induced antitumor responses ...
Xem chi tiết » -
2.CX-072 (pacmilimab), A Probody PD-L1 Inhibitor, In Combination ...
23 thg 7, 2021 · PROCLAIM-CX-072 (PRObody CLinical Assessment In Man, CX-072 Clinical Trial 001) is a first-in-human study evaluating the tolerability, and ...
Xem chi tiết » -
3.CX-072 (pacmilimab), A Probody PD-L1 Inhibitor, In ... - PubMed
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose- ...
Xem chi tiết » -
4.CX-072 (pacmilimab), A Probody ® PD-L1 Inhibitor, In Advanced Or ...
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Xem chi tiết » -
5.PROCLAIM-CX-072: Analysis Of Patients With Advanced Solid Tumors ...
25 thg 5, 2020 · CX-072 is an investigational PD-L1 PROBODY therapeutic that is preferentially activated in the tumor microenvironment (TME); localized ...
Xem chi tiết » -
6.PROCLAIM-CX-072: A Trial To Find Safe And Active Doses Of An ...
CX-072 is a Probody™ therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) ...
Xem chi tiết » -
7.Study Of PD-L1 Probody Therapeutic CX-072 In Combination With ...
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors ...
Xem chi tiết » -
8.Preliminary Results Of PROCLAIM-CX-072: The First-in-human, Dose ...
CX-072 is an anti–PD-L1 Probody™ therapeutic (Pb-Tx) designed to be preferentially activated by proteases in the tumor microenvironment and not in healthy ...
Xem chi tiết » -
9.The First-in-human, Dose-finding PROCLAIM-CX-072 Trial To Assess ...
Background: CX-072 is a novel protease activatable prodrug (Probody™ therapeutic) derived from a human monoclonal antibody against programmed cell death ligand ...
Xem chi tiết » -
10.Pipeline - CytomX
CytomX and AbbVie are co-developing CX-2029, a conditionally activated antibody-drug conjugate (ADC) directed against CD71, the transferrin receptor that is ...
Xem chi tiết » -
11.CX-072 In Patients With Advanced/recurrent Solid Tumours Or ...
An open-label, dose-finding and proof of concept study of the PD-L1 probody therapeutic, CX-072, as monotherapy and in combination with Yervoy® (Ipilimumab) ...
Xem chi tiết » -
12.Probody Therapeutic Design Of 89 Zr-CX-072 Promotes ...
Zr-CX-072 accumulates specifically in PD-L1–expressing tumors with limited uptake in murine peripheral lymphoid tissues. Our data may enable clinical evaluation ...
Xem chi tiết » -
13.Analysis Of Patients With Advanced Solid Tumors Receiving Long-term ...
Request PDF | PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, ...
Xem chi tiết » -
14.PROCLAIM-CX-072: A Phase 1/2 Trial To Find The Best Dose And Test ...
Purpose of trial The aim of this trial is to test whether CX-072 on its own or in combination with other treatments is safe and effective for people with ...
Xem chi tiết »